Global Cardiometabolic Disease Drug Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.

Published Jul 07, 2025

Length 113 Pages

SKU # APRC20339143

Description

Summary

According to APO Research, The global Cardiometabolic Disease Drug market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Cardiometabolic Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Cardiometabolic Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Cardiometabolic Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Cardiometabolic Disease Drug include Qilu Pharmaceutical, Merck, Roche Holding AG, Chengda Pharmaceutical, ZMC, Taj Pharma, Sydler Group, Space Biology and Servier, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Cardiometabolic Disease Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiometabolic Disease Drug.

The Cardiometabolic Disease Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Cardiometabolic Disease Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Cardiometabolic Disease Drug Segment by Company

Qilu Pharmaceutical
Merck
Roche Holding AG
Chengda Pharmaceutical
ZMC
Taj Pharma
Sydler Group
Space Biology
Servier
Northeast Pharmaceutical
NHU
Lonza Group
Kingdomway
Kaneka
Hengtai Chemical
Biosint
Abbott
Cardiometabolic Disease Drug Segment by Type

Coenzyme Q10
Cyclic Adenosine Monophosphate
Trimetazidine
L-carnitine
Others
Cardiometabolic Disease Drug Segment by Application

Retail Pharmacy
Online Sales
Hospital
Clinic
Others
Cardiometabolic Disease Drug Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cardiometabolic Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cardiometabolic Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cardiometabolic Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cardiometabolic Disease Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Cardiometabolic Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

1 Market Overview: 1.1 Product Definition; 1.2 Global Market Growth Prospects; 1.2.1 Global Cardiometabolic Disease Drug Market Size Estimates and Forecasts (2020-2031); 1.2.2 Global Cardiometabolic Disease Drug Sales Estimates and Forecasts (2020-2031); 1.3 Cardiometabolic Disease Drug Market by Type; 1.3.1 Coenzyme Q10; 1.3.2 Cyclic Adenosine Monophosphate; 1.3.3 Trimetazidine; 1.3.4 L-carnitine; 1.3.5 Others; 1.4 Global Cardiometabolic Disease Drug Market Size by Type; 1.4.1 Global Cardiometabolic Disease Drug Market Size Overview by Type (2020-2031); 1.4.2 Global Cardiometabolic Disease Drug Historic Market Size Review by Type (2020-2025); 1.4.3 Global Cardiometabolic Disease Drug Forecasted Market Size by Type (2026-2031); 1.5 Key Regions Market Size by Type; 1.5.1 North America Cardiometabolic Disease Drug Sales Breakdown by Type (2020-2025); 1.5.2 Europe Cardiometabolic Disease Drug Sales Breakdown by Type (2020-2025); 1.5.3 Asia-Pacific Cardiometabolic Disease Drug Sales Breakdown by Type (2020-2025); 1.5.4 South America Cardiometabolic Disease Drug Sales Breakdown by Type (2020-2025); 1.5.5 Middle East and Africa Cardiometabolic Disease Drug Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics: 2.1 Cardiometabolic Disease Drug Industry Trends; 2.2 Cardiometabolic Disease Drug Industry Drivers; 2.3 Cardiometabolic Disease Drug Industry Opportunities and Challenges; 2.4 Cardiometabolic Disease Drug Industry Restraints
3 Market Competitive Landscape by Company: 3.1 Global Top Players by Cardiometabolic Disease Drug Revenue (2020-2025); 3.2 Global Top Players by Cardiometabolic Disease Drug Sales (2020-2025); 3.3 Global Top Players by Cardiometabolic Disease Drug Price (2020-2025); 3.4 Global Cardiometabolic Disease Drug Industry Company Ranking, 2023 VS 2024 VS 2025; 3.5 Global Cardiometabolic Disease Drug Major Company Production Sites & Headquarters; 3.6 Global Cardiometabolic Disease Drug Company, Product Type & Application; 3.7 Global Cardiometabolic Disease Drug Company Establishment Date; 3.8 Market Competitive Analysis; 3.8.1 Global Cardiometabolic Disease Drug Market CR5 and HHI; 3.8.2 Global Top 5 and 10 Cardiometabolic Disease Drug Players Market Share by Revenue in 2024; 3.8.3 2023 Cardiometabolic Disease Drug Tier 1, Tier 2, and Tier 3
4 Cardiometabolic Disease Drug Regional Status and Outlook: 4.1 Global Cardiometabolic Disease Drug Market Size and CAGR by Region: 2020 VS 2024 VS 2031; 4.2 Global Cardiometabolic Disease Drug Historic Market Size by Region; 4.2.1 Global Cardiometabolic Disease Drug Sales in Volume by Region (2020-2025); 4.2.2 Global Cardiometabolic Disease Drug Sales in Value by Region (2020-2025); 4.2.3 Global Cardiometabolic Disease Drug Sales (Volume & Value), Price and Gross Margin (2020-2025); 4.3 Global Cardiometabolic Disease Drug Forecasted Market Size by Region; 4.3.1 Global Cardiometabolic Disease Drug Sales in Volume by Region (2026-2031); 4.3.2 Global Cardiometabolic Disease Drug Sales in Value by Region (2026-2031); 4.3.3 Global Cardiometabolic Disease Drug Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Cardiometabolic Disease Drug by Application: 5.1 Cardiometabolic Disease Drug Market by Application; 5.1.1 Retail Pharmacy; 5.1.2 Online Sales; 5.1.3 Hospital; 5.1.4 Clinic; 5.1.5 Others; 5.2 Global Cardiometabolic Disease Drug Market Size by Application; 5.2.1 Global Cardiometabolic Disease Drug Market Size Overview by Application (2020-2031); 5.2.2 Global Cardiometabolic Disease Drug Historic Market Size Review by Application (2020-2025); 5.2.3 Global Cardiometabolic Disease Drug Forecasted Market Size by Application (2026-2031); 5.3 Key Regions Market Size by Application; 5.3.1 North America Cardiometabolic Disease Drug Sales Breakdown by Application (2020-2025); 5.3.2 Europe Cardiometabolic Disease Drug Sales Breakdown by Application (2020-2025); 5.3.3 Asia-Pacific Cardiometabolic Disease Drug Sales Breakdown by Application (2020-2025); 5.3.4 South America Cardiometabolic Disease Drug Sales Breakdown by Application (2020-2025); 5.3.5 Middle East and Africa Cardiometabolic Disease Drug Sales Breakdown by Application (2020-2025)
6 Company Profiles: 6.1 Qilu Pharmaceutical; 6.1.1 Qilu Pharmaceutical Comapny Information; 6.1.2 Qilu Pharmaceutical Business Overview; 6.1.3 Qilu Pharmaceutical Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.1.4 Qilu Pharmaceutical Cardiometabolic Disease Drug Product Portfolio; 6.1.5 Qilu Pharmaceutical Recent Developments; 6.2 Merck; 6.2.1 Merck Comapny Information; 6.2.2 Merck Business Overview; 6.2.3 Merck Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.2.4 Merck Cardiometabolic Disease Drug Product Portfolio; 6.2.5 Merck Recent Developments; 6.3 Roche Holding AG; 6.3.1 Roche Holding AG Comapny Information; 6.3.2 Roche Holding AG Business Overview; 6.3.3 Roche Holding AG Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.3.4 Roche Holding AG Cardiometabolic Disease Drug Product Portfolio; 6.3.5 Roche Holding AG Recent Developments; 6.4 Chengda Pharmaceutical; 6.4.1 Chengda Pharmaceutical Comapny Information; 6.4.2 Chengda Pharmaceutical Business Overview; 6.4.3 Chengda Pharmaceutical Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.4.4 Chengda Pharmaceutical Cardiometabolic Disease Drug Product Portfolio; 6.4.5 Chengda Pharmaceutical Recent Developments; 6.5 ZMC; 6.5.1 ZMC Comapny Information; 6.5.2 ZMC Business Overview; 6.5.3 ZMC Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.5.4 ZMC Cardiometabolic Disease Drug Product Portfolio; 6.5.5 ZMC Recent Developments; 6.6 Taj Pharma; 6.6.1 Taj Pharma Comapny Information; 6.6.2 Taj Pharma Business Overview; 6.6.3 Taj Pharma Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.6.4 Taj Pharma Cardiometabolic Disease Drug Product Portfolio; 6.6.5 Taj Pharma Recent Developments; 6.7 Sydler Group; 6.7.1 Sydler Group Comapny Information; 6.7.2 Sydler Group Business Overview; 6.7.3 Sydler Group Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.7.4 Sydler Group Cardiometabolic Disease Drug Product Portfolio; 6.7.5 Sydler Group Recent Developments; 6.8 Space Biology; 6.8.1 Space Biology Comapny Information; 6.8.2 Space Biology Business Overview; 6.8.3 Space Biology Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.8.4 Space Biology Cardiometabolic Disease Drug Product Portfolio; 6.8.5 Space Biology Recent Developments; 6.9 Servier; 6.9.1 Servier Comapny Information; 6.9.2 Servier Business Overview; 6.9.3 Servier Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.9.4 Servier Cardiometabolic Disease Drug Product Portfolio; 6.9.5 Servier Recent Developments; 6.10 Northeast Pharmaceutical; 6.10.1 Northeast Pharmaceutical Comapny Information; 6.10.2 Northeast Pharmaceutical Business Overview; 6.10.3 Northeast Pharmaceutical Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.10.4 Northeast Pharmaceutical Cardiometabolic Disease Drug Product Portfolio; 6.10.5 Northeast Pharmaceutical Recent Developments; 6.11 NHU; 6.11.1 NHU Comapny Information; 6.11.2 NHU Business Overview; 6.11.3 NHU Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.11.4 NHU Cardiometabolic Disease Drug Product Portfolio; 6.11.5 NHU Recent Developments; 6.12 Lonza Group; 6.12.1 Lonza Group Comapny Information; 6.12.2 Lonza Group Business Overview; 6.12.3 Lonza Group Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.12.4 Lonza Group Cardiometabolic Disease Drug Product Portfolio; 6.12.5 Lonza Group Recent Developments; 6.13 Kingdomway; 6.13.1 Kingdomway Comapny Information; 6.13.2 Kingdomway Business Overview; 6.13.3 Kingdomway Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.13.4 Kingdomway Cardiometabolic Disease Drug Product Portfolio; 6.13.5 Kingdomway Recent Developments; 6.14 Kaneka; 6.14.1 Kaneka Comapny Information; 6.14.2 Kaneka Business Overview; 6.14.3 Kaneka Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.14.4 Kaneka Cardiometabolic Disease Drug Product Portfolio; 6.14.5 Kaneka Recent Developments; 6.15 Hengtai Chemical; 6.15.1 Hengtai Chemical Comapny Information; 6.15.2 Hengtai Chemical Business Overview; 6.15.3 Hengtai Chemical Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.15.4 Hengtai Chemical Cardiometabolic Disease Drug Product Portfolio; 6.15.5 Hengtai Chemical Recent Developments; 6.16 Biosint; 6.16.1 Biosint Comapny Information; 6.16.2 Biosint Business Overview; 6.16.3 Biosint Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.16.4 Biosint Cardiometabolic Disease Drug Product Portfolio; 6.16.5 Biosint Recent Developments; 6.17 Abbott; 6.17.1 Abbott Comapny Information; 6.17.2 Abbott Business Overview; 6.17.3 Abbott Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2020-2025); 6.17.4 Abbott Cardiometabolic Disease Drug Product Portfolio; 6.17.5 Abbott Recent Developments
7 North America by Country: 7.1 North America Cardiometabolic Disease Drug Sales by Country; 7.1.1 North America Cardiometabolic Disease Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031; 7.1.2 North America Cardiometabolic Disease Drug Sales by Country (2020-2025); 7.1.3 North America Cardiometabolic Disease Drug Sales Forecast by Country (2026-2031); 7.2 North America Cardiometabolic Disease Drug Market Size by Country; 7.2.1 North America Cardiometabolic Disease Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031; 7.2.2 North America Cardiometabolic Disease Drug Market Size by Country (2020-2025); 7.2.3 North America Cardiometabolic Disease Drug Market Size Forecast by Country (2026-2031)
8 Europe by Country: 8.1 Europe Cardiometabolic Disease Drug Sales by Country; 8.1.1 Europe Cardiometabolic Disease Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031; 8.1.2 Europe Cardiometabolic Disease Drug Sales by Country (2020-2025); 8.1.3 Europe Cardiometabolic Disease Drug Sales Forecast by Country (2026-2031); 8.2 Europe Cardiometabolic Disease Drug Market Size by Country; 8.2.1 Europe Cardiometabolic Disease Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031; 8.2.2 Europe Cardiometabolic Disease Drug Market Size by Country (2020-2025); 8.2.3 Europe Cardiometabolic Disease Drug Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country: 9.1 Asia-Pacific Cardiometabolic Disease Drug Sales by Country; 9.1.1 Asia-Pacific Cardiometabolic Disease Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031; 9.1.2 Asia-Pacific Cardiometabolic Disease Drug Sales by Country (2020-2025); 9.1.3 Asia-Pacific Cardiometabolic Disease Drug Sales Forecast by Country (2026-2031); 9.2 Asia-Pacific Cardiometabolic Disease Drug Market Size by Country; 9.2.1 Asia-Pacific Cardiometabolic Disease Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031; 9.2.2 Asia-Pacific Cardiometabolic Disease Drug Market Size by Country (2020-2025); 9.2.3 Asia-Pacific Cardiometabolic Disease Drug Market Size Forecast by Country (2026-2031)
10 South America by Country: 10.1 South America Cardiometabolic Disease Drug Sales by Country; 10.1.1 South America Cardiometabolic Disease Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031; 10.1.2 South America Cardiometabolic Disease Drug Sales by Country (2020-2025); 10.1.3 South America Cardiometabolic Disease Drug Sales Forecast by Country (2026-2031); 10.2 South America Cardiometabolic Disease Drug Market Size by Country; 10.2.1 South America Cardiometabolic Disease Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031; 10.2.2 South America Cardiometabolic Disease Drug Market Size by Country (2020-2025); 10.2.3 South America Cardiometabolic Disease Drug Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country: 11.1 Middle East and Africa Cardiometabolic Disease Drug Sales by Country; 11.1.1 Middle East and Africa Cardiometabolic Disease Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031; 11.1.2 Middle East and Africa Cardiometabolic Disease Drug Sales by Country (2020-2025); 11.1.3 Middle East and Africa Cardiometabolic Disease Drug Sales Forecast by Country (2026-2031); 11.2 Middle East and Africa Cardiometabolic Disease Drug Market Size by Country; 11.2.1 Middle East and Africa Cardiometabolic Disease Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031; 11.2.2 Middle East and Africa Cardiometabolic Disease Drug Market Size by Country (2020-2025); 11.2.3 Middle East and Africa Cardiometabolic Disease Drug Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis: 12.1 Cardiometabolic Disease Drug Value Chain Analysis; 12.1.1 Cardiometabolic Disease Drug Key Raw Materials; 12.1.2 Key Raw Materials Price; 12.1.3 Raw Materials Key Suppliers; 12.1.4 Manufacturing Cost Structure; 12.1.5 Cardiometabolic Disease Drug Production Mode & Process; 12.2 Cardiometabolic Disease Drug Sales Channels Analysis; 12.2.1 Direct Comparison with Distribution Share; 12.2.2 Cardiometabolic Disease Drug Distributors; 12.2.3 Cardiometabolic Disease Drug Customers
13 Concluding Insights
14 Appendix: 14.1 Reasons for Doing This Study; 14.2 Research Methodology; 14.3 Research Process; 14.4 Authors List of This Report; 14.5 Data Source; 14.5.1 Secondary Sources; 14.5.2 Primary Sources; 14.6 Disclaimer

Pricing

Currency Rates

Single User Email from Publisher $3,450
Global Site License Email from Publisher $6,900

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now